Ascletis Pharma Inc. has announced the selection of ASC37, its first oral GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development. In preclinical studies, ASC37 demonstrated significantly greater in vitro potency-approximately 5-fold for GLP-1R, 4-fold for GIPR, and 4-fold for GCGR-compared to retatrutide. The company plans to submit an Investigational New Drug Application $(IND)$ for ASC37 oral tablets to the U.S. Food and Drug Administration in the second quarter of 2026. These research results have been announced in advance of a planned conference call scheduled for December 1, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251130-11933721), on November 30, 2025, and is solely responsible for the information contained therein.